Physician profile
John Patrick Simmons
NPI 1235662768
$8,455.28
in general payments reported to CMS, 2019-2025
30 companies · $2,303 in 2025
The $2,303 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.25 · 2021: $26.41 · 2023: $4,022 · 2024: $2,085 · 2025: $2,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,152 · Education: $3,100 · Travel and Lodging: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,152.22 |
| Education | $3,099.95 |
| Travel and Lodging | $158.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,175.44 | 2023 | Ion, Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals Lp | $613.55 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.77 | 2023-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $436.44 | 2023-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $373.65 | 2020-2025 | |
| United Therapeutics Corporation | $367.65 | 2023-2025 | Tyvaso, Tyvaso |
| Glaxosmithkline, LLC. | $324.53 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $303.23 | 2023-2025 | Tezspire, Tavneos |
| Merck Sharp & Dohme LLC | $291.78 | 2023-2025 | Winrevair, Zerbaxa, Recarbrio |
| Regeneron Healthcare Solutions, INC. | $241.48 | 2023-2025 | Dupixent |
| Stryker Corporation | $198.84 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Actelion Pharmaceuticals US, INC. | $174.80 | 2024-2025 | Uptravi, Opsumit |
| Grifols USA, LLC | $161.21 | 2023-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $143.32 | 2025 | Yupelri |
| Penumbra, INC. | $142.22 | 2024 | Indigo System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $138.96 | 2021-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Electromed, INC. | $119.66 | 2023-2025 | Smartvest |
| Mylan Specialty L.P. | $114.03 | 2023-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Janssen Pharmaceuticals, INC | $96.06 | 2023-2024 | Xarelto |
| Verona Pharma, INC. | $71.59 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $65.51 | 2023-2024 | Sunosi |
| Pfizer INC. | $59.16 | 2024-2025 | |
| Inspire Medical Systems, INC. | $58.94 | 2023-2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $54.81 | 2024-2025 | Hyqvia |
| Vifor Pharma, INC. | $48.46 | 2025 | Zemaira |
| Genentech USA, INC. | $29.92 | 2024 | Xolair |
| 3b Medical, INC. | $21.34 | 2025 | Luna |
| Bayer Healthcare Pharmaceuticals INC. | $18.58 | 2025 | |
| Ani Pharmaceuticals, INC. | $18.40 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.